Cargando…
Dasatinib-loaded albumin nanoparticles possess diminished endothelial cell barrier disruption and retain potent anti-leukemia cell activity
Dasatinib (DAS), a second-generation tyrosine kinase inhibitor, is highly effective in treating chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. However, its clinical use is limited due to serious adverse effects. DAS can disrupt endothelial barrier integri...
Autores principales: | Dong, Chunling, Li, Bo, Li, Zhenyu, Shetty, Sreerama, Fu, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226540/ https://www.ncbi.nlm.nih.gov/pubmed/27391073 http://dx.doi.org/10.18632/oncotarget.10435 |
Ejemplares similares
-
Label-Retaining Cells in the Adult Murine Salivary Glands Possess Characteristics of Adult Progenitor Cells
por: Chibly, Alejandro M., et al.
Publicado: (2014) -
Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity
por: Calizo, Rhodora C., et al.
Publicado: (2019) -
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
por: Eustace, Alex J, et al.
Publicado: (2008) -
Dasatinib-Loaded Erythrocytes Trigger Apoptosis in Untreated Chronic Myelogenous Leukemic Cells: A Cellular Reservoir Participating in Dasatinib Efficiency
por: Airiau, Kelly, et al.
Publicado: (2018) -
Dasatinib is a potent enhancer for CAR T cell generation by CD3-targeted lentiviral vectors
por: Braun, Angela H., et al.
Publicado: (2022)